Two major human phenotypes of MICA molecules and their differential activation to NK cells via NKG2D receptor., PMID:40458406
Two major human phenotypes of MICA molecules and their differential activation to NK cells via NKG2D receptor., PMID:40458406
Inhibition of MCP1 (CCL2) Enhances Antitumor Activity of NK Cells Against HCC Cells Under Hypoxia., PMID:40430040
Inhibition of MCP1 (CCL2) Enhances Antitumor Activity of NK Cells Against HCC Cells Under Hypoxia., PMID:40430040
NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells., PMID:40421025
NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells., PMID:40421025
Complete CD16A Deficiency and Defective NK Cell Function in a Man Living with HIV., PMID:40411624
Complete CD16A Deficiency and Defective NK Cell Function in a Man Living with HIV., PMID:40411624
Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines., PMID:40391211
Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines., PMID:40391211
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry., PMID:40347474
Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry., PMID:40347474
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity., PMID:40274283
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity., PMID:40274283
From genetic variants to therapeutic targets: insights into understanding rheumatoid arthritis., PMID:40236704
From genetic variants to therapeutic targets: insights into understanding rheumatoid arthritis., PMID:40236704
23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation., PMID:40116579
23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation., PMID:40116579
Monocytes from patients with myelodysplastic syndrome inhibit natural killer cell-mediated antitumor function through the CD200/CD200R pathway., PMID:40049088
Monocytes from patients with myelodysplastic syndrome inhibit natural killer cell-mediated antitumor function through the CD200/CD200R pathway., PMID:40049088
BTK inhibitors enhance NKG2D ligand expression by regulating IL-10/STAT3 pathway in activated non-GCB diffuse large B-cell lymphoma cells., PMID:40029697
BTK inhibitors enhance NKG2D ligand expression by regulating IL-10/STAT3 pathway in activated non-GCB diffuse large B-cell lymphoma cells., PMID:40029697
Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis., PMID:40021214
Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis., PMID:40021214
Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma., PMID:39975034
Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma., PMID:39975034
Natural killer cell engagers for cancer immunotherapy., PMID:39911822
Natural killer cell engagers for cancer immunotherapy., PMID:39911822
Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma., PMID:39904787
Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma., PMID:39904787
A New Antibody-Cytokine Construct Targeting Natural Killer Cells: An Immunotherapeutic Approach to Chronic Lymphocytic Leukemia., PMID:39858511
A New Antibody-Cytokine Construct Targeting Natural Killer Cells: An Immunotherapeutic Approach to Chronic Lymphocytic Leukemia., PMID:39858511
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model., PMID:39763968
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model., PMID:39763968
Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials., PMID:39746495
Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials., PMID:39746495
Exosomal miR-552-5p Regulates the Role of NK Cells in EMT of Gastric Cancer via the PD-1/PD-L1 Axis., PMID:39744482
Exosomal miR-552-5p Regulates the Role of NK Cells in EMT of Gastric Cancer via the PD-1/PD-L1 Axis., PMID:39744482
Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal study., PMID:39724280
Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal study., PMID:39724280
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab., PMID:39699928
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab., PMID:39699928
Entry into the lytic cycle exposes EBV-infected cells to NK cell killing via upregulation of the MICB ligand for NKG2D and activation of the CD56bright and NKG2A+KIR+CD56dim subsets., PMID:39676862
Entry into the lytic cycle exposes EBV-infected cells to NK cell killing via upregulation of the MICB ligand for NKG2D and activation of the CD56bright and NKG2A+KIR+CD56dim subsets., PMID:39676862
γδ T cells in hematological malignancies: mechanisms and therapeutic strategies., PMID:39676818
γδ T cells in hematological malignancies: mechanisms and therapeutic strategies., PMID:39676818
Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager., PMID:39628574
Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager., PMID:39628574
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients., PMID:39612757
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients., PMID:39612757
Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligands., PMID:39582357
Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligands., PMID:39582357
MICA and NKG2D gene polymorphisms influence graft survival, and response to therapy in kidney transplantation., PMID:39575256
MICA and NKG2D gene polymorphisms influence graft survival, and response to therapy in kidney transplantation., PMID:39575256
Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas., PMID:39554029
Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas., PMID:39554029
Local treatment of HVJ-E with T cell costimulatory molecule stimulation elicits systemic anti-tumor effects., PMID:39534532
Local treatment of HVJ-E with T cell costimulatory molecule stimulation elicits systemic anti-tumor effects., PMID:39534532
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma., PMID:39504576
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma., PMID:39504576
IL-15-induced CD38+HLA-DR+CD8+ T cells correlate with liver injury via NKG2D in chronic hepatitis B cirrhosis., PMID:39416768
IL-15-induced CD38+HLA-DR+CD8+ T cells correlate with liver injury via NKG2D in chronic hepatitis B cirrhosis., PMID:39416768
CD56-targeted in vivo genetic engineering of natural killer cells mediates immunotherapy for acute myeloid leukemia., PMID:39363829
CD56-targeted in vivo genetic engineering of natural killer cells mediates immunotherapy for acute myeloid leukemia., PMID:39363829
Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans., PMID:39345527
Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans., PMID:39345527
Challenges in the Development of NK-92 Cells as an Effective Universal Off-the-Shelf Cellular Therapeutic., PMID:39291926
Challenges in the Development of NK-92 Cells as an Effective Universal Off-the-Shelf Cellular Therapeutic., PMID:39291926
Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective cohort study., PMID:39279428
Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective cohort study., PMID:39279428
Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies., PMID:39267747
Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies., PMID:39267747
A novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models., PMID:39211152
A novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models., PMID:39211152
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab., PMID:39209453
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab., PMID:39209453
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer., PMID:39190534
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer., PMID:39190534
Isolation of anti-tumor monoclonal antibodies targeting on MICA/B α3 domain by single B cell technology for colon cancer therapy., PMID:39170144
Isolation of anti-tumor monoclonal antibodies targeting on MICA/B α3 domain by single B cell technology for colon cancer therapy., PMID:39170144
Expression and function of the major histocompatibility complex (MHC) class I chain-related A (MICA)*010 in NK cell killing activity., PMID:39116667
Expression and function of the major histocompatibility complex (MHC) class I chain-related A (MICA)*010 in NK cell killing activity., PMID:39116667
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity., PMID:39112670
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity., PMID:39112670
Regulation of the PD-1/PD-L1 Axis and NK Cell Dysfunction by Exosomal miR-552-5p in Gastric Cancer., PMID:39020183
Regulation of the PD-1/PD-L1 Axis and NK Cell Dysfunction by Exosomal miR-552-5p in Gastric Cancer., PMID:39020183
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study., PMID:38898592
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study., PMID:38898592
Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors., PMID:38756234
Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors., PMID:38756234
Memory-like differentiation enhances NK cell responses against colorectal cancer., PMID:38737793
Memory-like differentiation enhances NK cell responses against colorectal cancer., PMID:38737793
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands., PMID:38731936
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands., PMID:38731936
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells., PMID:38724464
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells., PMID:38724464
Transmural Flow Upregulates PD-L1 Expression in Microvascular Networks., PMID:38696611
Transmural Flow Upregulates PD-L1 Expression in Microvascular Networks., PMID:38696611
For research use only. Not for human or drug use.
